Status:
COMPLETED
Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts
Lead Sponsor:
Zagazig University
Conditions:
Warts
Eligibility:
All Genders
9-45 years
Phase:
PHASE2
Brief Summary
The investigators explore the role of the complement pathway and T helper 1 immune response in clinical response to Candida immunotherapy via complement component and tumor necrosis factor, respective...
Detailed Description
39 patients are enrolled in the study They suffer from chronic recurrent cutaneous warts Patients receive Candida antigen immunotherapy vial intra-lesional injection every 2 weeks till complete resolu...
Eligibility Criteria
Inclusion
- Chronic multiple cutaneous
Exclusion
- Hypersensitivity to Candida antigen
- Fever
- Immunosuppressive disorders
- Previous wart therapy in the last month
Key Trial Info
Start Date :
July 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 3 2019
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT04399577
Start Date
July 1 2017
End Date
September 3 2019
Last Update
May 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zagazig University Faculty of Medicine
Zagazig, Sharqia Province, Egypt, 44519